Cargando…

Pharmacological targeting of glutamatergic neurons within the brainstem for weight reduction

Food intake and body weight are tightly regulated by neurons within specific brain regions, including the brainstem, where acute activation of dorsal raphe nucleus (DRN) glutamatergic neurons expressing the glutamate transporter Vglut3 (DRN(Vglut3)) drive a robust suppression of food intake and enha...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneeberger, Marc, Brice, Nicola L., Pellegrino, Kyle, Parolari, Luca, Shaked, Jordan T., Page, Keith J., Marchildon, François, Barrows, Douglas W., Carroll, Thomas S., Topilko, Thomas, Mulligan, Victoria M., Newman, Robert, Doyle, Kevin, Bürli, Roland, Barker, Daniel F., Glen, Angela, Ortuño, María José, Nectow, Alexander R., Renier, Nicolas, Cohen, Paul, Carlton, Mark, Heintz, Nathaniel, Friedman, Jeffrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684079/
https://www.ncbi.nlm.nih.gov/pubmed/36411386
http://dx.doi.org/10.1038/s42255-022-00677-8
Descripción
Sumario:Food intake and body weight are tightly regulated by neurons within specific brain regions, including the brainstem, where acute activation of dorsal raphe nucleus (DRN) glutamatergic neurons expressing the glutamate transporter Vglut3 (DRN(Vglut3)) drive a robust suppression of food intake and enhance locomotion. Activating Vglut3 neurons in DRN suppresses food intake and increases locomotion, suggesting that modulating the activity of these neurons might alter body weight. Here, we show that DRN(Vglut3) neurons project to the lateral hypothalamus (LHA), a canonical feeding center that also reduces food intake. Moreover, chronic DRN(Vglut3) activation reduces weight in both leptin-deficient (ob/ob) and leptin-resistant diet-induced obese (DIO) male mice. Molecular profiling revealed that the orexin 1 receptor (Hcrtr1) is highly enriched in DRN Vglut3 neurons, with limited expression elsewhere in the brain. Finally, an orally bioavailable, highly selective Hcrtr1 antagonist (CVN45502) significantly reduces feeding and body weight in DIO. Hcrtr1 is also co-expressed with Vglut3 in the human DRN, suggesting that there might be a similar effect in human. These results identify a potential therapy for obesity by targeting DRN(Vglut3) neurons while also establishing a general strategy for developing drugs for central nervous system disorders.